Global disruptive behavior disorders market is anticipated to show growth during the forecast period owing to the rising prevalence of these disorders. The Disruptive behavioral disorders include attention deficit hyperactivity disorder (ADHD), Oppositional defiant disorder and conduct disorder which has more prevalence in the children from 3- 17 years of age. Risk factors such as academic failure, child abuse, early pregnancies, parental mental illness, low social class and social incompetence are some of the factors responsible for disruptive behavioral disorders. Growing trends of unhealthy lifestyles are the major drivers of the market. Smoking during pregnancy and family history of behavioral disorders increase possibilities of ADHD to a greater extent. Increasing occurrence of co-morbid disorders is expected to ensure the growth of disruptive behavior disorders market during the forecast period. Lack of promising treatment options and increasing dependency on the psychotherapies and evidence based prevention are the factors anticipated to provide great platforms for the new drugs in the future. Growing interest of pharmaceutical companies to invest in R&D for the development of drugs for management and treatment of behavioral disorders is expected to push the market. Need for tools or techniques in the early diagnosis and prevention of the disruptive behavioral disorders is expected to provide platform for drug therapeutics used in the management of these disorders.
Based on the type, the disruptive behavior disorders market is segmented into Attention deficit Hyperactivity Disorder (ADHD), Conduct Disorder (CD) and Oppositional Defiant Disorder (ODD). ADHD captured the largest segment of the market owing to its global prevalence. According to CDC reports, the percentage of children diagnosed with ADHD in US alone went to 11% in 2011 from 7.8% in 2003. Significant Prevalence of ADHD in adults is expected to boost the market growth. Low percentage of patients diagnosed with ADHD provides platform for the efficient treatments for the disorder. Efforts taken by organizations such as WHO for spreading awareness of the condition are expected to fuel the market. Difficulty in diagnosing disorders such as ODD and CD until the progression is the factor hampering the growth of respective segments. Unmet needs in the treatment and management of ODD and CD offer great scope for the psychological drugs during the forecast period.
Geographically the disruptive behavioral disorders market is segmented into North America, Europe and Asia Pacific. Owing to the presence of excellent healthcare infrastructure and growing awareness of the people, North America captured larger part of the market. The dominance of the region in the market is expected to continue owing to the ongoing research and development of the drugs used in the management and treatment of behavioral disorders. According to the CDC report, 4.1 million of the U.S. schools going children were diagnosed for ADHD in year 2007 and 2.7 million were taking medications for the same. Presence of favorable government policies and demand for more effective treatments over available psychotherapies such as behavioral modification therapy and group based improvement therapies are the factors driving the market growth in the region. The market in the Asia Pacific region has shown the fastest growth with growing population and rising prevalence of behavioral disorders. According to the WHO estimates, China alone is estimated to witness more than 15 million cases of behavioral disorders during the forecast period. Developing economies, growing disposable incomes and rising awareness for the available treatments are the factors driving the growth of market positively in the forecast period.
Key players of disruptive behavioral disorders market are Eli Lilly and co., DURECT Corporation, Chelsea therapeutics, Bionomics ltd, Pfizer Inc, and Johnson & Johnson. Thought there are many major players, the disruptive behavioral disorder market has unmet needs with effective treatments. From the reports of archives of general psychology, of all the antipsychotic drugs prescribed during years 2005-2009, one third were prescribed to the children with disruptive behavioral disorders. Many companies have been caught for illegal marketing of the antipsychotic drugs for the treatment of ADHD in children. Many pipeline drugs going under clinical trials and waiting for their approval are expected to provide great scope for disruptive behavior disorders market growth. Strict regulations for the approval of new drugs may hamper the market growth.
Avail customized purchase options to meet your exact research needs:
Get your queries resolved from an industry expert.
Design an exclusive study to serve your research needs.
A testimonial for service in the form of BBB "A" Accreditation.
Your personal and confidential information is safe and secure.
"The quality of research they have done for us has been excellent..."